X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SEngine is also utilizing its precision oncology platform to inform drug discovery via strategic collaborations with pharma companies as well as, top cancer centers such as Dana-Farber and Gustave Roussy, while advancing its own pipeline of novel targeted drugs.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Washington Research Foundation
Deal Size: $19.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing July 28, 2022
Details:
SEngine and Oncodesign have initiated a joint research collaboration to evaluate the feasibility to convert the already identified Nanocyclix® inhibitor series into drug candidates that are likely to be effective in the clinic.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oncodesign
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 08, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
